U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07024563) titled 'Study of Ravulizumab in Pediatric Participants With Primary IgAN' on June 09.
Brief Summary: The primary objective of this study is to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with ravulizumab IV in pediatric participants to support the extrapolation of efficacy from the adult population.
Study Start Date: Sept. 26, 2025
Study Type: INTERVENTIONAL
Condition:
IgAN
IgAVN
Immunoglobulin A Nephropathy
Immunoglobulin A Vasculitis Associated Nephritis
Henoch-schonlein Purpura Nephritis
IgA Vasculitis
Intervention:
DRUG: Ravulizumab
Participants will receive Ravulizumab via intravenous (IV) infus...